Daridorexant

Status:

Red

Decision Date:

November 2022

Comments

RED: NICE TA922 Daridorexant for treating long-term insomnia. RED recommendation as holding position for TA compliance. ICB commissioned (Decision date - November 2023)

Red Drug Classifications

• 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
• 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
• 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)

search again